Clear Trail Advisors LLC Purchases 1,480 Shares of Amgen Inc. $AMGN

Clear Trail Advisors LLC increased its position in Amgen Inc. (NASDAQ:AMGN) by 18.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,539 shares of the medical research company’s stock after buying an additional 1,480 shares during the period. Clear Trail Advisors LLC’s holdings in Amgen were worth $3,356,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Norges Bank acquired a new position in shares of Amgen during the 4th quarter worth $2,164,162,000. Capital World Investors raised its holdings in shares of Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after purchasing an additional 4,302,237 shares in the last quarter. State Street Corp lifted its stake in shares of Amgen by 4.4% in the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock valued at $10,012,872,000 after purchasing an additional 1,287,310 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after purchasing an additional 1,035,779 shares during the last quarter. Finally, Amundi boosted its holdings in Amgen by 41.1% in the fourth quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock worth $1,111,854,000 after purchasing an additional 988,856 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

AMGN has been the topic of several analyst reports. Argus lowered their target price on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research report on Wednesday, May 20th. Mizuho upped their price target on Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 16th. Truist Financial increased their price objective on Amgen from $325.00 to $327.00 and gave the company a “hold” rating in a report on Friday, May 1st. Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a report on Sunday, June 14th. Finally, Leerink Partners reaffirmed a “market perform” rating and set a $355.00 target price on shares of Amgen in a research report on Thursday, March 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and an average target price of $354.42.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.85% of the stock is owned by company insiders.

Amgen Trading Up 2.1%

Amgen stock opened at $344.72 on Tuesday. The business has a 50 day moving average price of $340.50 and a two-hundred day moving average price of $345.86. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. Amgen Inc. has a 12 month low of $267.83 and a 12 month high of $391.29. The stock has a market cap of $186.05 billion, a price-to-earnings ratio of 23.99, a price-to-earnings-growth ratio of 3.39 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.Amgen’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the business posted $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts forecast that Amgen Inc. will post 22.38 EPS for the current year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.